The administration of BP-1-108 to MV-4-11 AML and K562 CML cell lines reduced STAT5 phosphorylation and the expression of target genes, such as cyclin D, MCL-1 and Myc [113]. The gene discussed is STAT5B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.